# Dapagliflozin With or Without Spironolactone for HFpEF

> **NCT05676684** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universidade do Porto** · enrollment: 108 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Spironolactone + Dapagliflozin

## Key facts

- **NCT ID:** NCT05676684
- **Lead sponsor:** Universidade do Porto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-15
- **Primary completion:** 2024-11-29
- **Final completion:** 2024-11-29
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676684, "Dapagliflozin With or Without Spironolactone for HFpEF". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05676684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*